Targeted Strategies for Today's Evolving Markets

MissionIR Blog

Stem Cells, Inc. (STEM) Starts Presentation at 2015 Marcum MicroCap Conference

Stem Cells is currently engaged in clinical development of its platform technology, HuCNS-SC(R) cells (purified human neural stem cells), as a potential treatment for disorders of the central nervous system (CNS). As the first ever to conduct a U.S. clinical trial with human neural stem cells, StemCells is the only company, to date, with established human safety and preliminary efficacy data for these cells. The company’s comprehensive patent portfolio includes seminal technology in cell biology, with neural stem cell patents covering compositions of matter, methods of manufacture and methods of use. For more information, visit the company’s website at

The Marcum MicroCap Conference is a forum where publicly traded companies with less than $500 million in market capitalization can network with the investment community. The two-day 2016 conference will include feature presentations by CEOs and CFOs from seven principal industry sectors, expert panels moderated by industry leaders, and the opportunity to meet with management of presenting companies on a one-on-one basis. Marcum is partnered with KCSA Strategic Communications to present this year's Marcum MicroCap Conference.
This entry was posted in Marcum MicroCap. Bookmark the permalink.

Comments are closed.